Search

Displaying results 5711 - 5720 of 10000 in total
  1. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is a fluorescent dye or luminescent agent.

  2. Drug

    Ilacirnon

    go.drugbank.com/drugs/DB16066
    Investigational

    Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).

  3. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. … Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  4. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  5. Drug

    Glyceryl monostearate

    go.drugbank.com/drugs/DB11250
    Approved

    Glycerol monostearate, commonly known as GMS, is the glycerol ester of stearic acid . It is commonly used as an emulsifier in foods.

  6. Drug

    Norbixin

    go.drugbank.com/drugs/DB15201
    Experimental

    Norbixin is under investigation in clinical trial NCT03820245 (Effect of Short-term Annatto Carotenoids Supplementation on Oxidative Stress Status in Healthy Individuals).

  7. Drug

    Batoclimab

    go.drugbank.com/drugs/DB16104
    Investigational

    Batoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).

  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  9. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

  10. Drug

    Managlinat dialanetil

    go.drugbank.com/drugs/DB05518
    Investigational

    CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.